These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8175282)

  • 1. Effects of recombinant human erythropoietin on sodium balance in nondialysed children with chronic renal failure.
    Kavukçu S; Saatci U; Ciliv G; Söylemezoğlu O; Bakkaloğlu A; Besbas N; Ozen S
    Int Urol Nephrol; 1993; 25(6):611-5. PubMed ID: 8175282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of recombinant human erythropoietin on the anemia of chronic renal failure.
    Urabe A; Takaku F; Mizoguchi H; Kubo K; Ota K; Shimizu N; Tanaka K; Mimura N; Nihei H; Koshikawa S
    Int J Cell Cloning; 1988 May; 6(3):179-91. PubMed ID: 3397592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Single weekly dose of recombinant erythropoietin in children with chronic renal insufficiency].
    Guízar JM; Gutiérrez MJ; Sánchez G; Kornhauser C
    Rev Invest Clin; 1996; 48(3):173-7. PubMed ID: 8966377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
    Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
    J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
    Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human erythropoietin (rhEPO) treatment potentiates growth hormone (GH) response to growth hormone releasing hormone (GHRH) stimulation in hemodialysis patients.
    Cremagnani L; Cantalamessa L; Orsatti A; Vigna L; Vallino F; Buccianti G
    Clin Nephrol; 1993 May; 39(5):282-6. PubMed ID: 8513607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of recombinant human erythropoietin on hematopoietic progenitors of chronic hemodialysis patients in vitro and in vivo.
    Hino M; Miyazono K; Urabe A; Takaku F
    Int J Cell Cloning; 1989 Jul; 7(4):257-63. PubMed ID: 2768843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily subcutaneous administration of recombinant human erythropoietin (rhEPO) in peritoneal dialysis patients: a European dose-response study.
    Faller B; Slingeneyer A; Waller M; Michel C; Grützmacher P; Müller HP; Barany P; Grabensee B; Issad B; Schmitt H
    Clin Nephrol; 1993 Sep; 40(3):168-75. PubMed ID: 8403573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of renal anemia with recombinant human erythropoietin].
    Burghard R; Gordjani N; Leititis JU
    Monatsschr Kinderheilkd; 1989 Mar; 137(3):174-7. PubMed ID: 2716749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of erythropoietin treatment on tissue oxygenation in patients with severe transfusion dependent renal anaemia.
    Landgraf H; Grützmacher P; Garcia-Bartels C; Bergmann M; Ehrly AM; Schoeppe W
    Eur J Med; 1993; 2(7):393-7. PubMed ID: 8258026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human erythropoietin in renal transplant recipients with renal anemia.
    Traindl O; Barnas U; Franz M; Falger S; Klauser R; Kovarik J; Graf H
    Clin Transplant; 1994 Feb; 8(1):45-8. PubMed ID: 8136567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo effects of recombinant human erythropoietin on bone marrow hematopoiesis in patients with chronic renal failure.
    Biljanović-Paunović L; Djukanović L; Lezaić V; Stojanović N; Marisavljević D; Pavlović-Kentera V
    Eur J Med Res; 1998 Dec; 3(12):564-70. PubMed ID: 9889177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rapid, progressive deterioration of renal function following erroneous administration of high doses of subcutaneous recombinant erythropoietin].
    Buemi M; Allegra A; Aloisi C; Corica F; Frisina N
    Riv Eur Sci Med Farmacol; 1996; 18(1):39-42. PubMed ID: 8766781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Human recombinant erythropoietin in treatment of uremic anemia in children with continual ambulatory peritoneal dialysis].
    Litwin M; Boguszewska-Baczkowska A; Jelonek A
    Pol Tyg Lek; 1994 Feb 7-14; 49(6-7):135-6. PubMed ID: 8090665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.